# Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization

> **NCT07512960** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fondation Hôpital Saint-Joseph** · enrollment: 614 (estimated)

## Conditions studied

- CLTI Defined as Rutherford Category 4 or 5

## Interventions

- **DRUG:** Clopidogrel 75 mg/day
- **OTHER:** Placebo Clopidogrel

## Key facts

- **NCT ID:** NCT07512960
- **Lead sponsor:** Fondation Hôpital Saint-Joseph
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2030-05-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 614 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07512960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07512960, "Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07512960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*